Decitabine Combination Therapy Pre-ASCT
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 36 patients (estimated)
- Sponsors
- Fred Hutchinson / University of Washington Cancer Consortium
- Tags
- Allogeneic Stem Cell Transplant, Hypomethylating Agents (HMA), Chemotherapy
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2118
- NCT Identifier
- NCT06928662
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.